Literature DB >> 34658053

Bayesian semiparametric joint modeling of longitudinal explanatory variables of mixed types and a binary outcome.

Woobeen Lim1, Michael L Pennell1, Michelle J Naughton2, Electra D Paskett2.   

Abstract

Many prospective biomedical studies collect longitudinal clinical and lifestyle data that are both continuous and discrete. In some studies, there is interest in the association between a binary outcome and the values of these longitudinal measurements at a specific time point. A common problem in these studies is inconsistency in timing of measurements and missing follow-ups which can lead to few measurements at the time of interest. Some methods have been developed to address this problem, but are only applicable to continuous measurements. To address this limitation, we propose a new class of joint models for a binary outcome and longitudinal explanatory variables of mixed types. The longitudinal model uses a latent normal random variable construction with regression splines to model time-dependent trends in mean with a Dirichlet Process prior assigned to random effects to relax distribution assumptions. We also standardize timing of the explanatory variables by relating the binary outcome to imputed longitudinal values at a set time point. The proposed model is evaluated through simulation studies and applied to data from a cancer survivor study of participants in the Women's Health Initiative.
© 2021 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Dirichlet process; cancer survivorship; imputation; insomnia; joint models

Mesh:

Year:  2021        PMID: 34658053      PMCID: PMC8716425          DOI: 10.1002/sim.9221

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.497


  26 in total

1.  Stochastic relaxation, gibbs distributions, and the bayesian restoration of images.

Authors:  S Geman; D Geman
Journal:  IEEE Trans Pattern Anal Mach Intell       Date:  1984-06       Impact factor: 6.226

2.  Joint models for a primary endpoint and multiple longitudinal covariate processes.

Authors:  Erning Li; Naisyin Wang; Nae-Yuh Wang
Journal:  Biometrics       Date:  2007-05-14       Impact factor: 2.571

3.  Evaluating surrogate markers of clinical outcome when measured with error.

Authors:  U G Dafni; A A Tsiatis
Journal:  Biometrics       Date:  1998-12       Impact factor: 2.571

4.  A joint model for survival and longitudinal data measured with error.

Authors:  M S Wulfsohn; A A Tsiatis
Journal:  Biometrics       Date:  1997-03       Impact factor: 2.571

5.  Predictors of vasomotor symptoms among breast cancer survivors.

Authors:  Katherine W Reeves; Michael Pennell; Randi E Foraker; Carolyn J Crandall; Marcia Stefanick; Electra D Paskett
Journal:  J Cancer Surviv       Date:  2018-02-09       Impact factor: 4.442

6.  Modelling progression of CD4-lymphocyte count and its relationship to survival time.

Authors:  V De Gruttola; X M Tu
Journal:  Biometrics       Date:  1994-12       Impact factor: 2.571

Review 7.  Insomnia and its treatment in women with breast cancer.

Authors:  Lavinia Fiorentino; Sonia Ancoli-Israel
Journal:  Sleep Med Rev       Date:  2006-09-11       Impact factor: 11.609

8.  On the Assessment of Monte Carlo Error in Simulation-Based Statistical Analyses.

Authors:  Elizabeth Koehler; Elizabeth Brown; Sebastien J-P A Haneuse
Journal:  Am Stat       Date:  2009-05-01       Impact factor: 8.710

9.  A Seminonparametric Approach to Joint Modeling of A Primary Binary Outcome and Longitudinal Data Measured at Discrete Informative Times.

Authors:  Song Yan; Daowen Zhang; Wenbin Lu; James A Grifo; Mengling Liu
Journal:  Stat Biosci       Date:  2012-11-01

10.  Pre-diagnostic Sleep Duration and Sleep Quality in Relation to Subsequent Cancer Survival.

Authors:  Amanda I Phipps; Parveen Bhatti; Marian L Neuhouser; Chu Chen; Tracy E Crane; Candyce H Kroenke; Heather Ochs-Balcom; Michelle Rissling; Beverly M Snively; Marcia L Stefanick; Miriam M Treggiari; Nathaniel F Watson
Journal:  J Clin Sleep Med       Date:  2016-04-15       Impact factor: 4.062

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.